Literature DB >> 24599932

Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel.

Jean E Abraham1, Qi Guo, Leila Dorling, Jonathan Tyrer, Susan Ingle, Richard Hardy, Anne-Laure Vallier, Louise Hiller, Russell Burns, Linda Jones, Sarah J Bowden, Janet A Dunn, Christopher J Poole, Carlos Caldas, Paul P D Pharoah, Helena M Earl.   

Abstract

PURPOSE: Associations between taxane-related sensory neuropathy (TRSN) and single-nucleotide polymorphisms (SNP) have previously been reported, but few have been replicated in large, independent validation studies. This study evaluates the association between previously investigated SNPs and TRSN, using genotype data from a study of chemotherapy-related toxicity in patients with breast cancer. EXPERIMENTAL
DESIGN: We investigated 73 SNPs in 50 genes for their contribution to TRSN risk, using genotype data from 1,303 European patients. TRSN was assessed using National Cancer Institute common toxicity criteria for adverse events classification. Unconditional logistic regression evaluated the association between each SNP and TRSN risk (primary analysis). Cox regression analysis assessed the association between each SNP and cumulative taxane dose causing the first reported moderate/severe TRSN (secondary analysis). The admixture likelihood (AML) test, which considers all SNPs with a prior probability of association with TRSN together, tested the hypothesis that certain SNPs are truly associated.
RESULTS: The AML test provided strong evidence for the association of some SNPs with TRSN (P = 0.023). The two most significantly associated SNPs were rs3213619(ABCB1) [OR = 0.47; 95% confidence interval (CI), 0.28-0.79; P = 0.004] and rs9501929(TUBB2A) (OR = 1.80; 95% CI, 1.20-2.72; P = 0.005). A further 9 SNPs were significant at P-value ≤ 0.05.
CONCLUSION: This is currently the largest study investigating SNPs associated with TRSN. We found strong evidence that SNPs within genes in taxane pharmacokinetic and pharmacodynamic pathways contribute to TRSN risk. However, a large proportion of the inter-individual variability in TRSN remains unexplained. Further validated results from GWAS will help to identify new pathways, genes, and SNPs involved in TRSN susceptibility. ©2014 AACR.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24599932     DOI: 10.1158/1078-0432.CCR-13-3232

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  45 in total

Review 1.  Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview.

Authors:  Alexandre Chan; Daniel L Hertz; Manuel Morales; Elizabeth J Adams; Sharon Gordon; Chia Jie Tan; Nathan P Staff; Jayesh Kamath; Jeong Oh; Shivani Shinde; Doreen Pon; Niharkia Dixit; James D'Olimpio; Cristina Dumitrescu; Margherita Gobbo; Kord Kober; Samantha Mayo; Linda Pang; Ishwaria Subbiah; Andreas S Beutler; Katherine B Peters; Charles Loprinzi; Maryam B Lustberg
Journal:  Support Care Cancer       Date:  2019-07-30       Impact factor: 3.603

Review 2.  Genome-Wide Association Studies of Chemotherapeutic Toxicities: Genomics of Inequality.

Authors:  Brandon Mapes; Omar El Charif; Shereen Al-Sawwaf; M Eileen Dolan
Journal:  Clin Cancer Res       Date:  2017-04-25       Impact factor: 12.531

Review 3.  Chemotherapy-induced peripheral neurotoxicity: management informed by pharmacogenetics.

Authors:  Andreas A Argyriou; Jordi Bruna; Armando A Genazzani; Guido Cavaletti
Journal:  Nat Rev Neurol       Date:  2017-06-30       Impact factor: 42.937

4.  Genome-wide meta-analyses identifies novel taxane-induced peripheral neuropathy-associated loci.

Authors:  Lara E Sucheston-Campbell; Alyssa I Clay-Gilmour; William E Barlow; G Thomas Budd; Daniel O Stram; Christopher A Haiman; Xin Sheng; Li Yan; Gary Zirpoli; Song Yao; Chen Jiang; Kouros Owzar; Dawn Hershman; Kathy S Albain; Daniel F Hayes; Halle C Moore; Timothy J Hobday; James A Stewart; Abbas Rizvi; Claudine Isaacs; Muhammad Salim; Jule R Gralow; Gabriel N Hortobagyi; Robert B Livingston; Deanna L Kroetz; Christine B Ambrosone
Journal:  Pharmacogenet Genomics       Date:  2018-02       Impact factor: 2.089

5.  P-Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer.

Authors:  Tore B Stage; Christina Mortensen; Sehbar Khalaf; Vivien Steffensen; Helen S Hammer; Chenling Xiong; Flemming Nielsen; Oliver Poetz; Åsa Fex Svenningsen; Cristina Rodriguez-Antona; Deanna L Kroetz
Journal:  Clin Pharmacol Ther       Date:  2020-05-23       Impact factor: 6.875

6.  A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.

Authors:  Eva Ciruelos; María Apellániz-Ruiz; Blanca Cantos; Noelia Martinez-Jáñez; Coralia Bueno-Muiño; Maria-Jose Echarri; Santos Enrech; Juan-Antonio Guerra; Luis Manso; Tomas Pascual; Cristina Dominguez; Juan-Francisco Gonzalo; Juan-Luis Sanz; Cristina Rodriguez-Antona; Juan-Manuel Sepúlveda
Journal:  Oncologist       Date:  2019-04-25

Review 7.  Chemotherapy-induced peripheral neuropathy: A current review.

Authors:  Nathan P Staff; Anna Grisold; Wolfgang Grisold; Anthony J Windebank
Journal:  Ann Neurol       Date:  2017-06-05       Impact factor: 10.422

8.  Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199.

Authors:  Bryan P Schneider; Lang Li; Milan Radovich; Tatiana Foroud; George W Sledge; Fei Shen; Kathy D Miller; David A Flockhart; Guanglong Jiang; Gail Vance; Laura Gardner; Matteo Vatta; Shaochun Bai; Dongbing Lai; Daniel Koller; Fengmin Zhao; Anne O'Neill; Mary Lou Smith; Elda Railey; Carol White; Ann Partridge; Joseph Sparano; Nancy E Davidson
Journal:  Clin Cancer Res       Date:  2015-07-02       Impact factor: 12.531

9.  Supplement Use and Chemotherapy-Induced Peripheral Neuropathy in a Cooperative Group Trial (S0221): The DELCaP Study.

Authors:  Gary R Zirpoli; Susan E McCann; Lara E Sucheston-Campbell; Dawn L Hershman; Gregory Ciupak; Warren Davis; Joseph M Unger; Halle C F Moore; James A Stewart; Claudine Isaacs; Timothy J Hobday; Muhammad Salim; Gabriel N Hortobagyi; Julie R Gralow; G Thomas Budd; Kathy S Albain; Christine B Ambrosone
Journal:  J Natl Cancer Inst       Date:  2017-12-01       Impact factor: 13.506

Review 10.  Pathogenesis of paclitaxel-induced peripheral neuropathy: A current review of in vitro and in vivo findings using rodent and human model systems.

Authors:  Nathan P Staff; Jill C Fehrenbacher; Martial Caillaud; M Imad Damaj; Rosalind A Segal; Sandra Rieger
Journal:  Exp Neurol       Date:  2019-11-21       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.